Stephen Robert Marder MD
Professor at UCLA Director, Section on Psychosis - UCLA Neuropsychiatric Institute and Hospital Director, Section on Psychosis - UCLA Semel Institute Professor and Director, Section on Psychosis UCLA Semel Institute of Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA Director, MIRECC - VA Greater Los Angeles Healthcare System
Join to view full profile
11301 Wilshire Blvd., MIRECC-210ALos Angeles, CA 90073
Phone+1 310-268-3647
Fax+1 310-268-3647
Dr. Marder is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Psychiatry, 1972 - 1975
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1971
Certifications & Licensure
CA State Medical License 1972 - 2027
MD State Medical License 1976 - 1979
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- America's Top Doctors Castle Connolly, 2002-2014
Clinical Trials
Publications & Presentations
PubMed
- Characterizing the Impacts of Psychosis on Methamphetamine Use Patterns Among Individuals with Methamphetamine-Associated Psychosis.Michael F Zito, Hilary M Wright, Sonya E Gabrielian, Stephen R Marder, Larissa J Mooney
Substance Use & Addiction Journal. 2026-08-13 - The NLRP3 inflammasome: pathophysiology and therapeutic implications for schizophrenia and neuropsychiatric disorders.Jonah Im, Madeline Mai, Kailin Mimaki, Lara Tang, Stephen Marder
Molecular Psychiatry. 2026-08-12 - Withania somnifera (Ashwagandha) as an Adjunctive Treatment to Antipsychotic Medications for Patients With Schizophrenia.Stephen R Marder, Deanna L Kelly, Gerard DeVera, Jennifer Osing Zaranski, Fiona Whelan
Journal of Clinical Psychopharmacology. 2026-07-17
Journal Articles
- Reliability and Validity of the Self-Report Version of the Apathy Evaluation Scale in First-Episode Psychosis: Concordance with the Clinical Version at Baseline and 12...Stephen Marder, MD, Psychiatry Research
Authored Content
- A Dose-Finding Study of Oxytocin Using Neurophysiological Measures of Social ProcessingJuly 2018
Press Mentions
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program with Evenamide as Add-on Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)March 17th, 2025
Amyloid Fibers Reveal Themselves with near‐InfraredSeptember 3rd, 2020
FDA Approves Daily Asenapine PatchNovember 7th, 2019
Grant Support
- Enhancing Community Integration for Homeless VeteransVA GREATER LOS ANGELES HEALTHCARE SYSTEM2020–2025
- Opportunities For Innovative Drug Development For SchizophreniaNational Institute Of Mental Health2009–2010
- Treatment Units For Research On Neurocognition &Schizophrenia (TURNS)National Institute Of Mental Health2007
- Relapse Prevention: Long-Acting Atypical AntipsychoticsNational Institute Of Mental Health2006
- Management For Risk Of Relapse In SchizophreniaNational Institute Of Mental Health1993–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
